Reference : From the design to the clinical application of thromboxane modulators
Scientific journals : Letter to the editor
Life sciences : Veterinary medicine & animal health
http://hdl.handle.net/2268/18029
From the design to the clinical application of thromboxane modulators
English
Dogné, Jean-Michel [Université de Liège - ULg > Département de pharmacie > Département de pharmacie >]
Hanson, Julien mailto [Université de Liège - ULg > Département de pharmacie > Chimie pharmaceutique >]
de Leval, Xavier [> > > >]
Pratico, Domenico [> > > >]
Pace-Asciak, Cecil R. [> > > >]
Drion, Pierre mailto [Université de Liège - ULg > > Centre animalier universitaire - Animalerie centrale >]
Pirotte, Bernard mailto [Université de Liège - ULg > Département de pharmacie > Chimie pharmaceutique >]
Ruan, Ke-He [> > > >]
2006
Current Pharmaceutical Design
Bentham Science Publ Ltd
12
8
903-923
Yes (verified by ORBi)
International
1381-6128
1873-4286
Sharjah
The Netherlands
[en] Arachidonic acid (AA) metabolites are key mediators involved in the pathogenesis of numerous cardiovascular, pulmonary, inflammatory, and thromboembolic diseases. One of these bioactive metabolites of particular importance is thromboxane A(2) (TXA(2)). It is produced by the action of thromboxane synthase on the prostaglandin endoperoxide H-2 (PGH(2)) which results from the enzymatic transformation of AA by the cyclooxygenases. It is a potent inducer of platelet aggregation, vasoconstriction and bronchoconstriction, and has been involved in a series of major pathophysiological conditions. Therefore, TXA(2) receptor antagonists, thromboxane synthase inhibitors and drugs combining both properties have been developed by different laboratories since the early 1980s. Several Compounds have been launched on the market and others are tinder clinical evaluation. In the first part of this review. we will describe the physiological properties of TXA(2), thromboxane synthase and thromboxane receptors. The second part is dedicated to a description of each class of thromboxane modulators with the advantages and disadvantages they offer. In the third part. we aim to describe recent studies performed with the most interesting thromboxane modulators in major pathologies: myocardial infarction and thrombosis, atherosclerosis, diabetes, pulmonary embolism, septic shock.. preeclampsia, and asthma. Each pathology will be systematically reviewed. Finally, in the last part we will highlight the latest perspectives in drug design of thromboxane modulators and in their future therapeutic applications such as cancer, metastasis and angiogenesis.
Researchers ; Professionals
http://hdl.handle.net/2268/18029
also: http://hdl.handle.net/2268/23157

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Dogne et al.pdfPublisher postprint519.31 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.